Zacks Investment Research downgraded Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to Sell in a report released today.
- Updated: October 12, 2016
Zacks Investment Research has downgraded Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to Sell in a report released on 10/12/2016.
Previously on 10/07/2016, HC Wainwright released a statement about Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) increased the target price from $0.00 to $22.00. At the time, this indicated a possible upside of 0.66%.
Just yesterday Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) traded -4.65% lower at $12.70. Zynerba Pharmaceuticals Inc’s 50-day moving average is $11.28 and its 200-day moving average is $9.18. The last stock price is up 31.98% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 197,680 shares of ZYNE traded hands, down from an average trading volume of 234,328
Recent Performance Chart
Zynerba Pharmaceuticals Inc has 52 week low of $4.64 and a 52 week high of $21.56 and has a market capitalization of $0.
Brief Synopsis On Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.